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Purpose: To determine the optimal dose of single fraction conventional palliative radiation therapy for
the relief of pain caused by bone metastases.
Material and methods: Ovid version of EMBASE and EMBASE Classic, MEDLINE, the Cochrane Database of
Systematic Reviews and the Cochrane Central Register of Controlled Trials were searched for relevant
randomised controlled trials. Pain response data were standardised according to the clinical trial end-
points recommended by the International Bone Metastases Consensus Working Party.
Results: From 2696 references we selected 26 articles for review. These described 24 trials that cumula-
tively randomised 3233 patients to 28 single fraction arms: two arms received 4 Gy, one 5 Gy, one 6 Gy,
twenty-two 8 Gy, one 10 Gy and one 8–15 Gy. Eighty-four percent of all patients received 8 Gy and this
imbalance precluded formal modelling analyses for different doses. Efﬁcacy endpoints and pain assess-
ment times varied. In general, higher doses produced better pain response rates. The overall (OR) and com-
plete (CR) pain response rates for different doses according to available intention-to-treat (ITT) and
assessable patient (A) ﬁgures were: 4 Gy [OR(ITT) = 23–47%, OR(A) = 44–47%, CR(ITT) = 15–18%,
CR(A) = 15–26%], 5 Gy [OR(A) = 72%, CR(A) = 55%], 6 Gy [OR(ITT&A) = 65%, CR(ITT&A) = 21%], 8 Gy
[OR(ITT) = 21–81%, OR(A) = 31–93%, CR(ITT) = 9–52%, CR(A) = 14–57%], 10 Gy [OR(A) = 84%, CR(A) = 39%].
In trials that directly compared different single fraction doses, 8 Gy was statistically superior to 4 Gy.
Conclusions: 8 Gy was by far the most commonly administered single fraction dose within 24 randomised
trials of conventional radiation therapy for the palliation of bone metastases. 8 Gy should be the standard
dose against which future treatments are compared due to its reproducible pain response rate and its estab-
lished safe proﬁle. The optimal dose for the relief of pain remains an open question, however, 8 Gy produced
statistically superior pain response rates compared to 4 Gy in trials directly comparing those doses, and in
general across all trials doses of 8 Gy or more produced numerically superior pain response rates compared
to doses less than 8 Gy.
Open access under CC BY-NC-ND license. 2012 Elsevier Ireland Ltd.
Radiotherapy and Oncology 106 (2013) 5–14Randomised controlled trials have been comparing single frac-
tion (SF) and multiple fraction (MF) conventional external beam
radiation therapy for the palliation of pain due to bone metastases
for decades. A recent meta-analysis of 25 of these trials reported
that SF and MF regimens provided complete pain responses for
23% and 24% of patients respectively, and overall pain responses
(complete and partial responses combined) for 60% and 61% [1].
International practice guidelines [2–4] now support the assertion
[5] that SF radiation therapy is the standard of care for the relief
of pain due to uncomplicated bone metastases.
However, the optimal SF dose required to achieve pain relief is
unknown. SF doses varied among the trials within the meta-anal-Radiation Oncology, Odette
University of Toronto, 2075
Chow).
er CC BY-NC-ND license.ysis, and other trials speciﬁcally comparing different SF regimens
to each other [6–8] were not analysed. As the goal of palliative
radiation therapy is to deliver the lowest possible effective dose
in the interest of minimising iatrogenic toxicity, not knowing the
optimal SF dose is an important gap in our knowledge. As a ﬁrst
step in addressing this gap we performed a systematic review of
SF treatment arms within all randomised controlled trials of con-
ventional external beam radiation therapy for the palliation of
bone metastases. We hypothesised that higher doses lead to supe-
rior pain response rates.
Material and methods
Search strategy
We used relevant subject headings and keywords to search the
following databases without language restrictions: EMBASE (1980
to Week 38 2012), EMBASE Classic (1947 to 1979), Ovid MEDLINE
6 Single fraction palliative radiation therapy(1950 to September 24 2012), the Cochrane Database of Systematic
Reviews (2005 to September 2012) and the Cochrane Central Reg-
ister of Controlled Trials (September 2012).
The abstracts or available data from the references obtained
from this search were read independently by three authors (KD,
LM, LZ) to include or exclude references for full-text article review.Selection criteria for full-text article review
References were included if they described journal articles
reporting phase III trials that randomised patients to at least one
arm of SF conventional external beam radiation therapy for the
palliation of bone metastases. Relevant references not clearly iden-
tifying patient populations, study designs or dose fractionation
regimens were included to be conservative. References were ex-
cluded if they were duplicates, or if they described: non-random-
ised or phase I–II trials, trials using radiation therapy speciﬁcally
for bone metastases causing spinal cord compression, trials involv-
ing hemi-body-, radiopharmaceutical- or stereotactic radiation
therapy, trials combining radiation therapy with other concurrent
local or systemic treatments, preliminary trial reports published
prior to complete patient enrolment, follow-up reports of previ-
ously published trials with no new relevant data, or conference
abstracts.Final selection
The full-text articles from the selected references were read
independently by two authors (KD, LZ) to choose the ﬁnal set of2696 references identified
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40 full-text article
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Fig. 1. Flow diagram of literature search. SF =articles for review and analysis. The reference lists of these articles
were also reviewed, and references from relevant titles were ob-
tained and reviewed according to the above selection criteria. Dis-
crepancies for ﬁnal selections between KD and LZ were resolved by
consensus. Google translator [9] and/or native speakers were used
to translate non-English articles.Data abstraction
Pain response rate data were abstracted from full-text articles
in the ﬁnal set and categorised to enable comparison. A complete
pain response (CR) was deﬁned as the absence of pain following
radiation therapy. An overall pain response (OR) was deﬁned as
an improvement in pain following radiation therapy (these re-
sponses included CRs when they were available). The speciﬁc crite-
ria for improvement otherwise were deﬁned by the individual
trials; a pragmatic approach that has been employed in previous
systematic reviews [1,10]. The pain response data from each trial
that were ultimately analysed were those that most closely
approximated the recommended endpoints for clinical trials in pal-
liative radiation therapy for bone metastases established by the
International Bone Metastases Consensus Working Party [11,12].
Pain response assessment times closest to 4–8 weeks following
radiation therapy were selected, as historically this is a common
time for evaluating response within trials, and it is a clinically
important time when re-treatment begins to be considered
[13,14]. If trials reported pain response rates that controlled for
re-treatment, these rates were used preferentially over those that
did not. Other data abstracted from ﬁnal set articles included cita- through 
eened 
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Table 1
Randomised trials of conventional radiation therapy for the palliation of bone metastases that included a single fraction arm, organised by publication year. BPTWP = Bone Pain
Trial Working Party, CR = complete pain response, ECOG = Eastern Cooperative Oncology Group, EORTC QLQ = European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire, Gy = Gray, KPS = Karnofsky Performance Scale score, mo = month, n/a = not available, OR = overall pain response, QOL = quality of life, RT = radiation
therapy, RTOG = Radiation Therapy Oncology Group, WHO =World Health Organisation, VAS = visual analogue scale, wk = week, yr = year.
Author year Treatment
arms
Key eligibility criteria Pain measurements Pain response criteria from
trials as reported
Other prospective
assessments
Price 1986
[18]
8 Gy  1
vs.
3 Gy  10
Any cancer, prognosis P6 wk, no
pathologic fracture of long bone, no
previous RT in same site, no change in
systemic therapy within 6 wk of RT
Patient records pain in diary
at same time daily for 4 wk
then once weekly
Pain 4-point scale: none, mild,
moderate, severe
Follow-up duration: 3 mo
Response: improvement in
pain by P1 category
Complete response: no pain
Analgesics, toxicities
Cole 1989
[19]
8 Gy  1
vs.
4 Gy  6
Any cancer, no spinal cord compression,
no peripheral nerve compression, no
actual or threatened pathologic fracture,
no previous RT to trial site
Physician records pain
monthly
Patient records pain in diary
daily for 4 wk
Pain 5-point scale: criteria not
speciﬁed
Follow-up duration: 6 mo
Excellent response:
improvement in pain by P2
categories
Good response: improvement
in pain by 1 category
Poor response: no
improvement in, or
worsening pain
KPS, analgesics, toxicities
Kagei 1990
[20]
8 Gy  1
10 Gy  1
12 Gy  1
15 Gy  1
vs.
5 Gy  4
5 Gy  5
5 Gy  6
Carcinomas Pain 4-point scale Response: improvement in
pain by P1 category
Not translated
Hoskin
1992 [6]
4 Gy  1
vs.
8 Gy  1
Any cancer, prognosis P6 wk, no
pathologic fracture
Patient records pain at
baseline and at 2, 4, 8, 12 wk
Pain 4-point scale: none, mild,
moderate, severe
Response: improvement in
pain by P1 category
Complete response: no pain
Re-treatments, analgesics
Gaze 1997
[21]
10 Gy  1
vs.
4.5 Gy  5
Epithelial cancers, prognosis P4 wk, no
spinal cord compression, no vertebral
collapse above L2, no actual or
threatened pathologic fracture, no
previous surgery or RT to trial site, no
new concurrent systemic therapy on
trial
Physician records pain at 1, 3–
4 wk post-RT, then q2 mo
Patient records pain in diary
weekly
Pain 5-point scale: pain free,
mild discomfort, moderate
pain, severe pain, intractable
pain
Response: improvement in
pain by P1 category
Complete response: no pain
Complete combined
response: no pain and no
analgesics
ECOG/WHO performance
status, Spitzer’s QOL index,
Hospital Anxiety and
Depression Questionnaire,
analgesics, toxicities
Foro 1998
[15]
8 Gy  1
vs. 5 Gy x 3
vs. 3 Gy x
10
Any cancer, any prognosis, one painful
site, no risk of spinal cord compression
or pathologic fracture
Patient records pain at
baseline and at 1 mo post-RT,
then q3 mo
Pain VAS
Follow-up duration: 1 yr or
death
Response: improvement in
pain by P2 on VAS
WHO toxicity, analgesics
Jeremic
1998 [7]
4 Gy x 1 vs.
6 Gy x 1 vs.
8 Gy x 1
Any cancer, prognosis P8 weeks, no
ribs, clavicles, scapulae or sternum as
trial site, no spinal cord compression, no
pathologic fracture, no previous surgery
or RT to trial site
Patient records pain at
baseline and at 1, 2, 3, 8, 12,
24 weeks
Pain 4-point scale: none, mild,
moderate, severe
Partial response:
improvement in pain by P1
category with pain still
existing
Complete response: no pain
No response: no
improvement in, or
worsening pain
Analgesics, RTOG and EORTC
toxicities
Nielsen
1998
[22]
8 Gy  1
vs.
5 Gy  4
Any cancer, no spinal cord compression,
no pathologic fractures (except vertebral
compression fractures), no previous RT
to trial site
Patient records pain at
baseline and at 4, 8, 12, 20 wk
post-RT commencement
Pain VAS and 5-point scale:
none, mild, moderate, severe,
excruciating
Follow-up duration: 20 wk
Response:P50% reduction on
VAS or improvement in pain
by P1 category
Complete response: no pain
Progression: increase in pain
or increase in morphine dose
Analgesics, QOL
BPTWP
1999
[23]
8 Gy  1
vs.
4 Gy  5
vs.
3 Gy  10
Any cancer, no spinal cord compression,
no pathologic fracture of long bone, no
previous RT to trial site
Patient records pain at
baseline and a 2 weeks, 1, 2, 3,
4, 5, 6, 8, 10, 12 mo post-RT
commencement
Pain 4-point scale: none, a
little, quite a bit, very much
Response: improvement in
pain by P1 category
Complete response: no pain
Analgesics, toxicities
Koswig
1999
[24]
8 Gy  1
vs.
3 Gy  10
Breast, prostate, lung or kidney cancer,
no previous RT to trial site
Pain recorded at baseline, and
immediately post-RT and 3,
6 weeks post-RT completion
Pain intensity 4-point scale:
none, low, moderate, strong
Pain frequency 4-point scale:
never, occasionally,
intermittently, constantly
Analgesic 4-point scale: no
Response: based on pain
intensity, pain frequency,
analgesic type and analgesic
frequency
Bone density
(continued on next page)
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Table 1 (continued)
Author year Treatment
arms
Key eligibility criteria Pain measurements Pain response criteria from
trials as reported
Other prospective
assessments
drug, peripheral analgesics,
centrally acting analgesics,
peripherally and centrally
acting analgesics
Analgesic frequency 4-point
scale: no intake, if necessary,
daily, more than daily
Patient subjective pain report
daily
Steenland
1999
[25]
van der
Linden
2004
[26]
8 Gy  1
vs.
4 Gy  6
Any solid cancer except kidney or
melanoma, no cervical spine trial site,
pain of P2 on 11-point scale, no spinal
cord compression, no pathologic
fracture requiring surgery, no previous
RT to trial site
Patient records pain at
baseline and weekly to 3 mo,
then q4 wk to 2 yr
Pain 11-point scale: 0 (no
pain at all) -10 (worst
imaginable pain)
Partial response: decrease in
pain score by P2 with no
analgesic increase OR
analgesic decrease without
pain increase
Complete response: pain
score of 0 with no analgesic
increase
Analgesics, Rotterdam
Symptom Checklist for QOL,
toxicities
Ozsaran
2001
[27]
8 Gy  1
vs.
4 Gy  5
vs.
3 Gy  10
Any cancer, no spinal cord compression,
no previous surgery for pathologic
fracture or RT to trial site
Pain rated at baseline, 10d, 1,
3 mo post-RT
Pain 4-point scale: no pain,
mild pain, moderate pain,
severe pain
Response: mild pain relief
(10–50% response) OR
considerable pain relief,
minimal analgesic
requirement (60–90%
response)
Complete response: complete
pain relief (100% response)
Analgesics, KPS
Altundag
2002 [8]
5 Gy  1
vs.
8 Gy  1
vs.
3 Gy  10
Any cancer, no spinal cord compression,
no pathologic fracture, no previous
surgery or RT to trial site
Patient rates pain at baseline
and at 15, 30, 45–60d post-RT
completion
Pain VAS
Partial response: greater than
50% improvement on VAS
Complete response: no pain
on VAS
Analgesics
Sarkar 2002
[28]
8 Gy  1
vs.
3 Gy  10
Any cancer, no previous RT to trial site Physician rates pain at
baseline and at 1, 2, 3, 4, 8 wk
post-RT completion
Pain 4-point scale: none, mild,
moderate, severe
Response: improvement in
pain by P1 category
Badzio 2003
[29]
8 Gy  1
vs.
4 Gy  5
Any cancer, no previous pathologic
fracture or RT to trial site
Patient records pain at
baseline and at 2, 3, 8, then
q4 wk post-RT
Pain 4-point scale: none, mild,
moderate, severe
Response: improvement in
pain by by P1 category OR
signiﬁcant decrease in
analgesics with stable pain
Complete response: no pain
and no analgesics
Analgesics
Hartsell
2005
[30]
8 Gy  1
vs.
3 Gy  10
Breast or prostate cancer, prognosis
P3 mo, no spinal cord compression, no
pathologic fracture or impending
fracture, no previous or planned surgery
or previous RT to trial site
Patient records pain at
baseline and at 2, 4 wk, 2, 3, 6,
9, 12, 18, 24, 30, 36, 48, 60 mo
Pain 11-point scale: 0–10
Stable response: change in
pain up to 1 in either
direction
Partial response:
improvement in pain by P2
Complete response: no pain
Analgesics, Functional
Assessment of Cancer
Therapy Questionnaire,
Health Utilities Index III
Roos 2005
[31]
8 Gy  1
vs.
4 Gy  5
Any cancer, prognosis P6 wk, no spinal
cord or cauda equina compression, no
pathologic fracture, no previous RT to
trial site
Patient records pain at
baseline and at 2, 4 wk, 2,
3 mo then q3 mo post-RT
until treatment failure or
death
Pain 4-point scale: none, mild,
moderate, severe
Response: improvement in
pain by P1 category with no
increase in analgesics
Complete response: no pain
and no analgesics or adjuvant
analgesics
Analgesics and adjuvants,
RTOG toxicities
El- Shenshawy 2006 [17] 8 Gy  1 vs. 4 Gy  5 vs.
3 Gy  10
Any solid tumour, no spinal
cord compression, no
pathologic fracture except
vertebral compression
fractures
Patient records pain at
baseline and at 1, 3–4 wk,
q1 mo post-RT
Pain 5-point scale: 0
(completely pain free) – 4
(intractable pain)
Response: improvement in pain byP1 category
Complete response: no pain
Complete combined response: no
pain and no analgesics
Analgesics, ECOG
performance status, nausea,
vomiting, tiredness, lassitude
Kaasa 2006
[32]
Sande
2009
[33]
8 Gy  1
vs.
3 Gy  10
Any cancer, KPS >40, no spinal cord
compression, no need for surgery, no
previous RT to trial site
Patient records pain at
baseline and at 4, 8, 12, 20,
28 wk post-RT
Pain 4-point scale: not at all, a
little, quite a bit, very much
Response: Reduction in pain
intensity on the EORTC QLQ
C30 pain scale
Analgesics, QOL (EORTC
QLQ-C30), fatigue
(questoinnaire), nausea,
diarrhoea
Hamouda
2007
[34]
8 Gy  1
vs.
2 Gy  20
Epithelial cancers, no pathologic
fracture, no previous RT or surgery to
trial site
Patient records pain at
baseline and at 2, 4, 8, 12, 16,
20, 24 wk post-RT
Graduated visual analogue
scale (VAS): 0 (no pain) – 10
Response: reduction ofP50%
on VAS
Complete response: 0 on VAS
Analgesics, ECOG
performance status
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Table 1 (continued)
Author year Treatment
arms
Key eligibility criteria Pain measurements Pain response criteria from
trials as reported
Other prospective
assessments
(pain as bad as you can
imagine)
Safwat
2007
[16]
8 Gy  1
vs.
4 Gy  5
vs.
3 Gy  10
Any cancer, prognosis P3 mo, no spinal
cord or cauda equina compression, no RT
to trial site within 10 wk of trial
Patient records pain at
baseline and at 6 wk post-RT
Pain 5-point scale: 0 (none), 1
(mild), 2 (moderate), 3
(score), 4 (intolerable)
Response: improvement in
pain by P1 category
Analgesics, ECOG
performance status
Foro-
Arnalot
2008
[35]
8 Gy  1
vs.
3 Gy  10
Any cancer, single painful site, prognosis
P1 mo, no pathologic or impending
fracture, no spinal cord compression, no
previous RT to trial site
Patient records pain at
baseline and 3, 12, 24, 48 wk
post-RT
Pain 11-point scale: 0 (no
pain), 10 (maximum pain
intensity)
Partial response:
improvement in pain by P2
with no need for increasing
anlagesics
Complete response: no pain
with no need for increasing
analgesics
Overall response: partial and
complete responses
combined
Analgesics, KPS, toxicities
Amouzegar-
Hashemi
2008
[36]
8 Gy  1
vs.
3 Gy  10
Any cancer, uncomplicated bone site
only, no spinal cord compression, no
pathologic or impending fracture
Patient or care-giver records
pain at baseline and 1 mo
post-RT completion
Pain 5-question severity
questionnaire answers
translated into a 4-point
grade scale score: 1 (mild) to
4 (very severe)
Parial response:
improvement in pain by 1
grade
Complete response:
improvement in pain by P2
grades
Analgesics, haematologic
and gastrointestinal
toxicities
Akca 2010
[37]
8 Gy  1
vs.
4 Gy  5
vs.
3 Gy  10
Any cancer Patient records pain at
baseline and 30d post-RT
completion
Pain serverity 4-point scale: 0
(no pain), to 3 (severe)
Pain frequency 4-point scale:
0 (no pain) to 3 (constant)
Pain score: Pain
severity  pain frequency
Complete response: no pain
Analgesics
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ters, and rates of: retreatment, spinal cord or cauda equina com-
pression, pathological fractures, other toxicities and survival.Results
The initial database search produced 2696 references (Fig. 1).
During screening, the abstracts or available data from 40 of these
initially satisﬁed the selection criteria and their full-text articles
were obtained. Seventeen of the 38 were excluded after reading
the full-text articles but 3 new references from full-text reference
lists were selected and later retained after reading their respective
full-text articles [15–17]. Ultimately 26 articles reporting on 24
clinical trials formed the ﬁnal article set for analysis [6–8,15–37]
(Fig. 1). Two of the 24 trials were ﬁrst published between 1986
and 1989, nine between 1990 and 1999 and 13 from 2000 on-
wards. Two of the 24 trials were each analysed using data from
both an original and a follow-up article [25,26,32,33] (Table 1).
Two trials compared SF arms only [6,7] and the remaining 22 trials
compared SF and MF arms (Fig. 1). One small trial permitted four
doses to be administered within each of its SF and MF arms but re-
ported only pooled data for those two arms [20]. Data from this
trial were used for overall SF analyses but not individual SF dose
analyses.
Combining data from the 24 trials, 3233 patients were cumula-
tively randomised to 28 SF treatment arms (Table 2). One small
three-arm trial did not report the distribution of the 25 total pa-
tients within its SF and two MF arms, so its SF patients were not
included in the 3233 count [37]. Seven unique SF doses were
administered within the 24 trials although the small four-SF dose
trial mentioned above [20] was the only one to administer 12 Gy
and 15 Gy, and the number of patients receiving those doses was
not reported. Of the remaining ﬁve unique SF doses, 8 Gy was byfar the most common and was administered to 84% of the 3233 to-
tal patients. The breakdown of patients according to dose was:
4 Gy (two arms, total n = 246), 5 Gy (one arm, total n = 14), 6 Gy
(one arm, n = 108), 8 Gy (22 arms, total n = 2717), and 10 Gy (one
arm, n = 134).
Pain response rates that could be analysed were reported by all
but two [32,33,37] of the 24 trials (Table 2). Intention-to-treat
rates were available for 20 trials, assessable patient rates for 21,
and both for 19. Primary pain response criteria varied and were
based on qualitative categorical assessments (e.g. no pain, mild
pain) in 16 trials, on quantitative assessments (e.g. ordinal rating
scales) in six trials and it was not clear in two trials. Pain response
assessment times selected for analysis ranged from 3–12 weeks
following radiation therapy for 18 trials, and times were either be-
yond 12 weeks or were unclear six trials.
Three trials directly compared different SF arms. The ﬁrst trial,
published in 1992 (n = 270) reported a superior actuarial pain re-
sponse rate at 4 weeks for 8 Gy (76%) compared to 4 Gy (53%),
p < 0.01 [6]. The second trial, published in 1998 (n = 327) reported
superior overall pain response rates at 4 weeks for 8 Gy (74%) com-
pared to 4 Gy (47%) p = 0.000049, and for 6 Gy (65%) compared to
4 Gy p = 0.0075, but not for 8 Gy compared to 6 Gy p = 0.16 [7].
The third trial, published in 2002 (n = 42) reported a non-superior
assessable patient pain response rate within 60 days for 8 Gy (76%)
compared to 5 Gy (72%) p > 0.05 [8].
After data from all 24 trials were categorised according to our
pre-deﬁned response rate deﬁnitions, the overall- and complete
pain response rates for different SF doses were ultimately analysed
with descriptive statistics only due to the marked imbalance be-
tween dose level patient numbers. In general, higher doses pro-
duced numerically higher response rates (Table 2). For the two
4 Gy arms, the intention-to-treat overall pain response rates were
32% [6] and 47% [7] and the assessable patient overall pain re-
Table 2
Pain response data for single fraction arms, organised by dose. A = assessable patients, CR = complete pain response rate, d = days, Gy = gray, ITT = intention-to-treat,
mo = months, n/a = not available, OR = overall pain response rate, RT = radiation therapy, VAS = visual analogue scale, wk = weeks, yr = years.
Author year n
(SF arm)
Dose Time of pain assessment Pain response criteria from trials used for
synthesis
Pain response rates (# of responses/# of
randomisations = rate)
Overall pain response rate
(OR)
Complete pain response
rate (CR)
ITT A ITT A
Hoskin 1992 [6]
n = 137
4 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
44 /137 = 32% 44/99 = 44% 24 /
137 = 18%
25/98 = 26%
Jeremic 1998 [7]
n = 109
4 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
51/109 = 47% 51/109 = 47% 16/
109 = 15%
16/
109 = 15%
Altundag 2002 [8]
n = 14
5 Gy Either 15, 30, or 45–60d
post-RT completion
OR: improvement by >50% on VAS
CR: no pain on VAS
n/a 72% n/a 55%
Jeremic 1998 [7]
n = 108
6 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
70/108 = 65% 70/108 = 65% 23/
108 = 21%
23/
108 = 21%
Price 1986 [18]
n = 140
8 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
29/140 = 21% 29/43 = 67% 13/140 = 9% 13/49 = 27%
Cole 1989 [19]
n = 16
8 Gy Time of the best pain
score to 6 mo
OR: ‘Excellent response’
CR: n/a
13/16 = 81% 13/14 = 93% n/a n/a
Hoskin 1992 [6]
n = 133
8 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
67/133 = 50% 67/97 = 69% 22/
133 = 17%
22/96 = 23%
Foro 1998 [15]
n = 25
8 Gy Either 1 mo or q3 mo
post-RT
to 1 yr
OR: improvement in pain by P2 on VAS
CR: n/a
19/25 = 76% 19/25 = 76% n/a n/a
Jeremic 1998 [7]
n = 110
8 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
81/110 = 74% 81/110 = 74% 28/
110 = 25%
28/
110 = 25%
Nielsen 1998 [22]
n = 122
8 Gy Time of symptom
progression or increased
opioids
OR:P50% pain reduction on VAS or
improvement in pain by P1 category
CR: no pain
VAS criteria 52/
122 = 43%
Categorical
criteria 37/
122 = 30%
VAS criteria 52/
106 = 49%
Categorical
criteria 37/
60 = 62%
n/a n/a
BPTWP 1999 [23]
n = 383
8 Gy Time of ﬁrst pain
response
OR: improvement in pain by P1 category
CR: no pain
274/383 = 72% 274/351 = 78% 199/
383 = 52%
199/
351 = 57%
Koswig 1999 [24]
n = 52
8 Gy Either immediately or 3,
6 wk post-RT completion
OR: n/a
CR: n/a
78% 31%
Steenland 1999 [25]
van der Linden
2004 [26]
n = 579
8 Gy Time period from
baseline
until the ﬁrst of either:
1 yr or retreatment
OR: decrease in pain of P2 with no analgesic
increase OR analgesic decrease without pain
increase
CR: pain score of 0 with no analgesic increase
395/579 = 68% 395/556 = 71% 78/
579 = 13%
78/
556 = 14%
Ozsaran 2001 [27]
n = 36
8 Gy 1 mo OR: any amount of ‘palliation’ (either 0–50,
50–80, or 80–100%)
CR: n/a
25/36 = 69% 25/36 = 69% n/a n/a
Altundag 2002 [8]
n = 15
8 Gy Either 15, 30, or 45–60 d
post-RT completion
OR: greater than 50% improvement on VAS
CR: no pain on VAS
n/a 76% n/a 41%
Sarkar 2002 [28]
n = 35
8 Gy 4 wk OR: improvement in pain by P1 category
CR: no pain
21/35 = 60% 21/31 = 68% 11/35 = 31% 11/31 = 35%
Badzio 2003 [29]
n = 57
8 Gy n/a OR: improvement in pain by P1 category
CR: no pain and no analgesics
53/72
sites = 74%
53/64
sites = 83%
23/72
lesions = 32%
23/64
lesions = 36%
Hartsell 2005 [30]
n = 455
8 Gy 3 mo OR: improvement in pain by P2
CR: no pain
187/455 = 41% 187/288 = 65% 44/
455 = 10%
44/
288 = 15%
Roos 2005 [31]
n = 137
8 Gy Within 2 mo OR: improvement in pain by P1 category
with no increase in analgesia
CR: no pain and no analgesia or adjuvant
analgesia
73/137 = 53% 73/127 = 57% 35/
137 = 26%
35/
127 = 28%
El-Shenshawy
2006 [17]
n = 50
8 Gy Either 1, 4, or 12 wk
post-RT; time with best
response
OR: improvement in pain by P1 category
CR: no pain and no analgesia
39/50 = 78% 39/50 = 78% 9/50 = 18% 9/50 = 18%
Kaasa 2006 [32]
Sande 2009 [33]
n = 186
8 Gy 12 wk n/a n/a n/a n/a n/a
Hamouda 2007 [34]
n = 52
8 Gy 4 wk OR: improvement of P50% on VAS
CR: 0 on VAS.
40/52 = 77% 40/50 = 80% 20/52 = 38% 20/50 = 40%
Safwat 2007 [16]
n = 20
8 Gy 6 wk OR: improvement in pain by P1 category
CR: n/a
14/20 = 70% 14/20 = 70% n/a n/a
Foro-Arnalot
2008 [35]
n = 78
8 Gy 3 wk OR: improvement in pain by P2 with no need
for increasing anlagesia
CR: no pain with no need for increasing
analgesia
59/78 = 75% 59/76 = 78% 12/78 = 15% 12/76 = 16%
Amouzegar-
Hashemi
2008 [36]
n = 36
8 Gy 1 mo OR: improvement in pain by P1 grade
CR: n/a
21/36 = 58% 21/27 = 78% n/a n/a
Akca 2010 [37]
n = n/a
8 Gy 30 d post-RT CR: no pain n/a n/a n/a n/a
(continued on next page)
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Table 2 (continued)
Author year n (SF
arm)
Dose Time of pain assessment Pain response criteria from trials used for
synthesis
Pain response rates (# of responses/# of
randomisations = rate)
Overall pain response rate
(OR)
Complete pain response
rate (CR)
ITT A ITT A
Gaze 1997 [21]
n = 134
10 Gy Either 1 wk or 1 mo
post-RT; time with best
response
OR: improvement in pain byP 1 category
CR: no pain
n/a 108/
129 = 84%
n/a 50/
129 = 39%
Kagei 1990 [20]
n = 14
8Gy
10Gy
12Gy
15 Gy
8 wk OR: improvement in pain byP 1 category
CR: no pain
12/14 = 86% 12/14 = 86% 8/14 = 57% 8/14 = 57%
K. Dennis et al. / Radiotherapy and Oncology 106 (2013) 5–14 11sponse rates were 44% [6] and 47% [7]. The intention-to-treat com-
plete pain response rates were 18% [6] and 15% [7] and the assess-
able complete pain response rates were 26% [6] and 15% [7]. For
the only 5 Gy arm the intention-to-treat response rates were not
available but the assessable patient overall pain response rate
was 72% and the assessable patient complete pain response rate
was 55% [8]. For the only 6 Gy arm the intention-to-treat and
assessable patient overall pain response rates were both 65% and
the intention-to-treat and assessable patient complete pain re-
sponse rates were both 21% [7]. For the twenty-two 8 Gy arms
the intention-to-treat overall pain response rates ranged from
21% to 81% (data available for 19 of 22 arms), and the assessable
patient overall pain response rates ranged from 49% to 93%, (data
available for 20 of 22 arms). The intention-to-treat complete pain
response rates ranged from 9% to 52%, (data available for 13 of
22 arms), and the assessable patient complete pain response rates
ranged from 14% to 57%, (data available for 13 of 22 arms). For the
only 10 Gy arm the intention-to-treat response rates were not
available but the assessable patient overall pain response rate
was 84% and the assessable patient complete pain response rate
was 39% [21].
Toxicity data were inconsistently reported, in a mix of inten-
tion-to-treat and assessable patient ﬁgures (Table 3). No trends
were identiﬁed within these outcomes that favoured a speciﬁc
dose. Retreatment rates were available for 14 trials and 18 total
treatment arms. For two 4 Gy arms the intention-to-treat rates
were 20% [6] and 42% up to 8 weeks post-treatment [7]. For the
only 5 Gy arm, the assessable patient rate was 14% [8]. For the only
6 Gy arm the intention-to-treat rate was 44% up to 8 weeks post-
treatment [7]. For the 8 Gy arms intention-to-treat rates ranged
from 9% to 38% (data available for 13 of 22 arms). No rate was
available for 10 Gy. Spinal cord compression rates were available
for 7 trials and 9 total treatment arms. For the only 4 Gy arm the
intention-to-treat rate was 0% up to 8 weeks post-treatment and
4% beyond 8 weeks post-treatment [7]. No rate was available for
5 Gy. For the only 6 Gy arm the intention-to treat rate was 0% up
to 8 weeks post-treatment and 5% beyond 8 weeks post-treatment
[7]. For the 8 Gy arms the intention-to-treat rates ranged from 0%
to 7% (data available for 7 of 22 arms). No rate was available for
10 Gy. Pathologic fracture rates were available for 9 trials and 11
total treatment arms. For the only 4 Gy arm the intention-to-treat
rate was 0% up to 8 weeks post-treatment and 3% beyond 8 weeks
post-treatment [7]. No rate was available for 5 Gy. For the only
6 Gy arm the intention-to-treat rate was 0% up to 8 weeks post-
treatment and 3% beyond 8 weeks post-treatment [7]. For the
8 Gy arms the intention-to-treat rates ranged from 0% to 6% (data
available for 9 of 11 arms). No rate was available for 10 Gy. Other
toxicities that were reported as a function of dose were available
for 10 trials (Table 3). A nested toxicity sub-study [23] and study
arm subpopulation toxicity analyses [26,33] were excluded.
The most commonly reported of these other toxicities werenausea, vomiting and diarrhoea; grading systems were
heterogeneous.Discussion
This is the ﬁrst systematic review to focus on the relative efﬁ-
cacy of different doses of SF conventional external beam radiation
therapy for the relief of pain due to bone metastases. It updates a
narrative review of the topic that was published in 2001 [38].
Our analysis included data from 13 randomised trials that have
been published since that time.
We were not able to quantitatively determine if a SF dose re-
sponse exists because 84% of all patients analysed had received
the same 8 Gy dose. In fact, the last randomised trial investigating
a SF dose aside from 8 Gy was published 10 years ago [8]. The 11
trials published since then that we reviewed all used 8 Gy.
However, the three trials that directly compared different SF
doses [6–8] showed that higher doses indeed produce superior re-
sponse rates. All three contained an 8 Gy arm that was either sta-
tistically [6,7] or numerically [8] superior to a lower dose arm. The
authors of two of the trials [6,7] concluded that 8 Gy is likely the
lowest optimal SF dose, but that 4 Gy could still be used in the set-
ting of reduced normal tissue tolerance or retreatment.
But how do we reconcile this suggested dose response within a
small range of SF doses with the results of dozens of trials where SF
doses (mostly 8 Gy) produced equivalent response rates to much
higher cumulative MF doses [1,10]? One could hypothesise that
8 Gy is required to achieve a certain threshold of tumour cell kill
that ultimately translates into an ‘optimal’ pain response as mea-
sured in these trials. Lower doses may not achieve this threshold
(explaining the SF dose response), and higher cumulative doses
may not provide additional beneﬁt (explaining the overall equiva-
lency of SF and MF regimens). This seems plausible, however the
relationship between tumour cell kill and pain response is not
clear, nor are the exact mechanisms through which bone metasta-
ses produce pain [6,39].
There are beneﬁts to having considerable experience with the
8 Gy dose. The cumulative toxicity data show it to be a safe dose
to administer, and a retreatment rate of approximately 20% seems
stable (Table 3), [1]. It also establishes a clear standard against
which future radiation therapy doses or techniques should be com-
pared within clinical trials.
Interestingly however, the ostensibly similar 22 study arms that
used this ‘standard’ 8 Gy dose had a wide range of pain response
rates (Table 2). This is likely due in part to differences in eligibility
criteria, endpoint deﬁnitions or the timing of pain assessments be-
tween trials. We minimised these differences as much as possible
by using data from the trials that most closely approximated the
standardised endpoints recommended by the International Bone
Metastases Consensus Working Party [11,12]. Cultural inﬂuences
Table 3
Prospectively-evaluated rates of re-treatment, spinal cord compression, pathologic fracture, other toxicities and survival for single fraction treatment arms, organised by dose.
A = assessable patients, D = diarrhoea, d = days, G = grade, Gy = gray, ITT = intention-to-treat, Max = maximum, mo = months, Mod = moderate, N = nausea, n/a = not available,
RT = radiation therapy, SF = single fraction, V = vomiting, wk = weeks, yr = years.
Author year n (SF arm) Dose Retreatment Spinal cord
compression
Pathologic fractures Other key toxicities Survival
Hoskin 1992 [6]
n = 137
4 Gy 28/137 = 20% (ITT) n/a n/a n/a Median = 8 mo
Jeremic 1998 [7]
n = 109
4 Gy To 8 wk post-RT: 46/
109 = 42% (ITT&A)
To 8 wk post-RT:
0% (ITT&A)
Beyond 8 wk post-
RT: 4/109 = 4% (ITT)
4/61 = 7% (A)
To 8 wk post-RT:
0% (ITT&A)
Beyond 8 wk post-
RT: 3/109 = 3% (ITT)
3/48 = 6% (A)
G1–2 N/V to 8 wk post-
RT: 21/109 = 19%
(ITT&A)
G1–2 D to 8 wk post-RT:
14/109 = 13% (ITT&A)
Median = 30 wk
32% at 1 yr
12% at 2 yr
7% at 3 yr
Altundag 2002 [8]
n = 14
5 Gy To 12 mo post-RT
completion: 2/14 = 14%
(A)
n/a n/a n/a Median = 13 mo
Jeremic 1998 [7]
n = 108
6 Gy To 8 wk post RT: 47/
108 = 44% (ITT&A)
To 8 wk post-RT:
0% (ITT&A)
Beyond 8 wk post-
RT: 5/108 = 5% (ITT)
5/63 = 8% (A)
To 8 wk post-RT:
0% (ITT&A)
Beyond 8 wk post-
RT: 3/108 = 3% (ITT)
3/45 = 7% (A)
G1–2 N/V to 8 wk post-
RT: 20/108 = 18% (ITT&A)
G1–2 D to 8 wk post-RT:
12/108 = 11% (ITT&A)
Median = 36 wk
40% at 1 yr
17% at 2 yr
8% at 3 yr
Price 1986 [18]
n = 140
8 Gy 15/140 = 11% (ITT) 2/140 = 1% (ITT) 0% (ITT) n/a Median = 5 mo
Cole 1989 [19]
n = 16
8 Gy 25% n/a n/a N&V: 77%, D: 30%
Skin reaction: 30%
n/a
Hoskin 1992 [6]
n = 133
8 Gy 12/133 = 9% (ITT) n/a n/a n/a Median = 8 mo
Foro 1998 [15]
n = 25
8 Gy n/a n/a n/a n/a Median = 335d (all
patients, not just SF
arm)
Jeremic 1998 [7]
n = 110
8 Gy To 8 wk post RT: 42/
110 = 38% (ITT&A)
To 8 wk post-RT:
0% (ITT&A)
Beyond 8 wk post-
RT: 4/110 = 4% (ITT)
4/66 = 6% (A)
To 8 wk post-RT:
0% (ITT&A)
Beyond 8 wk post-
RT: 3/110 = 3% (ITT)
3/44 = 7% (A)
G1–2 N/V to 8 wk post-
RT: 24/110 = 22%
(ITT&A)
G1–2 D to 8 wk post-RT:
16/110 = 15% (ITT&A)
Median = 29 wk
32% at 1 yr
11% at 2 yr
10% at 3 yr
Nielsen 1998 [22]
n = 122
8 Gy 25/122 = 20% (ITT) n/a n/a n/a Median = 33 wk
30% at 1 yr
BPTWP 1999 [23]
n = 383
8 Gy To 12 mo: 76/383 = 20%
(ITT) 76/329 = 23% (A)
6/383 = 2% (ITT) 7/383 = 2% (ITT) n/a 43% at 1 yr
Koswig 1999 [24]
n = 52
8 Gy n/a n/a n/a n/a n/a
Steenland 1999 [25]
van der Linden
2004 [26]
n = 579
8 Gy 24% (ITT) 13/579 = 2% (ITT) 24/579 = 4% (ITT) n/a Median = 33 wk
Ozsaran 2001 [27]
n = 36
8 Gy n/a 0% (ITT&A) n/a n/a Median = 3 mo
Altundag 2002 [8]
n = 15
8 Gy To 11 mo post-RT
completion: 3/15 = 20%
(A)
n/a n/a n/a Median = 8.8 mo
Sarkar 2002 [28]
n = 35
8 Gy n/a n/a n/a N & V: Mild for 9/
31 = 29% (A)
Mod for 1/31 = 3% (A)
D: Mild for 3/31 = 10%
(A)
n/a
Badzio 2003 [29]
n = 57
8 Gy n/a n/a n/a n/a n/a
Hartsell 2005 [30]
n = 455
8 Gy To 3 yr post-RT: 76/
455 = 17% (ITT)
n/a 5% Max acute per patient:
G1: 43/433 = 10% (A)
G2: 31/433 = 7% (A)
G3: 11/433 = 3% (A)
Max late per patient: G1:
10/354 = 3% (A)
G2: 11/354 = 3% (A)
G3: 2/354 = 1% (A)
Median = 9.1 mo
41% at 1 yr
22% at 2 yr
Roos 2005 [31]
n = 137
8 Gy 40/137 = 29% (ITT)
40/127 = 31% (A)
9/137 = 7% (ITT)
9/127 = 7% (A)
6/137 = 4% (ITT)
6/127 = 5% (A)
n/a n/a
El-Shenshawy 2006 [17]
n = 50
8 Gy 11/50 = 22% (ITT&A) n/a 6% (ITT&A) G3 N: 12%
G4 N: 2%
G3 tiredness: 10%
G4 tiredness: 2%
Median = 31 wk
34% at 1 yr
Kaasa 2006 [32]
Sande 2009 [33]
n = 186
8 Gy 29/186 = 16% (ITT) 10/186 = 5% (ITT) 8/186 = 4% (ITT) n/a Median = 9.6 mo
Hamouda 2007 [34]
n = 52
8 Gy n/a n/a 3/52 = 6% (ITT)
3/50 = 6% (A)
n/a n/a
Safwat 2007 [16]
n = 20
8 Gy To 8 wk post-RT: 7/
20 = 35% (ITT&A)
n/a n/a n/a n/a
12 Single fraction palliative radiation therapy
Table 3 (continued)
Author year n (SF arm) Dose Retreatment Spinal cord
compression
Pathologic fractures Other key toxicities Survival
Foro-Arnalot 2008 [35]
n = 78
8 Gy 22/78 = 28% (ITT) n/a n/a G1 dermatitis: 8%
G2 dermatitis: 2%
Median = 28 wk
Amouzegar-
Hashemi 2008 [36]
n = 36
8 Gy n/a n/a n/a N & D: Mild in 3/36 = 8%
(ITT)
86% at 1 mo
Akca 2010 [37]
n = n/a
8 Gy n/a n/a n/a n/a n/a
Gaze 1997 [21]
n = 134
10 Gy n/a n/a n/a G1 N&V: 18% (A)
G2 N&V: 10% (A)
G3 N&V: 11% (A)
G4 N&V: 1% (A)
G1 tiredness: 35% (A)
G2 tiredness: 24% (A)
G3 tiredness: 10% (A)
G4 tiredness: 3% (A)
43% at 6 mo
22% at 1 yr
Kagei 1990 [20]
n = 14
8 Gy 10 Gy
12 Gy 15 Gy
Not translated Not translated Not translated n/a Not translated
K. Dennis et al. / Radiotherapy and Oncology 106 (2013) 5–14 13on the experience or reporting of pain could have also contributed
to the range of response rates, as trials were carried out in four dif-
ferent continents. Fortunately the three largest and most inﬂuen-
tial trials [23,25,30] were of high quality, were conducted within
multiple countries [23,30] and reported similar overall pain re-
sponse rates.
Although pain relief is often the most important goal in the
treatment of bone metastases, given that patients can now survive
longer after bone metastases are diagnosed than they typically
could years ago, future clinical trials involving SF radiation therapy
should also make local control an objective. The optimal SF dose for
the prevention of future pathological fractures or compression of
the spinal cord and other neural structures is unknown [1,40].
Some aspects of our study design warrant comment. We did not
analyse non-randomised SF cohorts, although many have been
published and summarised elsewhere [38]. Had we done so our
analysis would have included more patients receiving doses aside
from 8 Gy, but our selection criteria were designed to reduce the
risk of selection bias. We also did not analyse SF cohorts from ran-
domised trials speciﬁcally focussing on re-irradiation [41,42] or the
treatment of spinal cord compression [43,44]. SF radiation therapy
is indeed useful in these settings, but the goal of our review was to
inform the management of patients with de novo bone metastases
causing pain, rather than the management of patients with more
complicated lesions. Reviews of these topics are provided else-
where [45,46]. Finally, trials involving SF hemi-body radiation
therapy were also excluded as this technique is now uncommon,
and the potential for pain relief through systemic mechanisms un-
ique to large-ﬁeld treatments may have biased our ﬁndings [47].Conclusions
In summary, 8 Gy was by far the most commonly administered
SF dose within 24 randomised trials of conventional radiation ther-
apy for the palliation of bone metastases. This dose should be the
standard against which future treatments are compared due to
its reproducible pain response and retreatment rates, and its safe
proﬁle. Whether 8 Gy is the optimal SF dose for the relief of pain
is an open question, but data from the trials that directly compared
different SF doses [6,7] show that it is superior to 4 Gy.Conﬂicts of interest
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